Actively Recruiting
Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism
Led by Chinese Academy of Medical Sciences, Fuwai Hospital · Updated on 2026-01-09
172
Participants Needed
3
Research Sites
178 weeks
Total Duration
On this page
Sponsors
C
Chinese Academy of Medical Sciences, Fuwai Hospital
Lead Sponsor
S
Second Affiliated Hospital of Nanchang University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Idiopathic hyperaldosteronism (IHA) represents about 65% of primary hyperaldosteronism cases. Although mineralocorticoid receptor antagonists (MRAs) are the standard first-line treatment, they are often limited by adverse effects. Superselective adrenal artery embolization (SAAE) has been utilized for IHA over the last decade, yet comparative studies against MRAs are lacking. The objective of this study is to compare the safety and efficacy of SAAE and MRA to determine the feasibility of SAAE in treating IHA.
CONDITIONS
Official Title
Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 15 to 60 years, any sex
- Diagnosed with primary aldosteronism according to 2016 Endocrine Society guidelines
- Confirmed idiopathic hyperaldosteronism subtype
- Signed informed consent approved by ethics committee
You will not qualify if you...
- Unilateral adrenal hyperplasia
- Kidney failure with estimated glomerular filtration rate under 45 ml/min/1.73 m² or serum creatinine over 176 µmol/L
- Stroke, stent implantation, or heart attack within the past 3 months
- Severe allergy to contrast agents
- Women who are pregnant or planning pregnancy
- Serious organic diseases preventing SAAE treatment
- Other types of secondary hypertension
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China, 100037
Actively Recruiting
2
Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China, 330006
Actively Recruiting
3
The First Affiliated Hospital of Chengdu Medical College
Chengdu, Sichuan, China, 610500
Actively Recruiting
Research Team
X
Xiongjing Jiang, MD
CONTACT
H
Hui Dong, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here